ATE431551T1 - Marker für entzündungszustände - Google Patents

Marker für entzündungszustände

Info

Publication number
ATE431551T1
ATE431551T1 AT02707438T AT02707438T ATE431551T1 AT E431551 T1 ATE431551 T1 AT E431551T1 AT 02707438 T AT02707438 T AT 02707438T AT 02707438 T AT02707438 T AT 02707438T AT E431551 T1 ATE431551 T1 AT E431551T1
Authority
AT
Austria
Prior art keywords
inflammatory conditions
markers
pregnancy
marker
plasma protein
Prior art date
Application number
AT02707438T
Other languages
English (en)
Inventor
Cheryl Conover
Antonio Bayes-Genis
Holmes, Jr
Robert Schwartz
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Application granted granted Critical
Publication of ATE431551T1 publication Critical patent/ATE431551T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Rehabilitation Therapy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02707438T 2001-01-12 2002-01-11 Marker für entzündungszustände ATE431551T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/760,376 US6500630B2 (en) 2001-01-12 2001-01-12 Marker for inflammatory conditions
PCT/US2002/000762 WO2002056015A1 (en) 2001-01-12 2002-01-11 Marker for inflammatory conditions

Publications (1)

Publication Number Publication Date
ATE431551T1 true ATE431551T1 (de) 2009-05-15

Family

ID=25058918

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02707438T ATE431551T1 (de) 2001-01-12 2002-01-11 Marker für entzündungszustände

Country Status (11)

Country Link
US (9) US6500630B2 (de)
EP (2) EP2081026A1 (de)
JP (3) JP4338972B2 (de)
AT (1) ATE431551T1 (de)
AU (1) AU2002241845B2 (de)
CA (1) CA2434512C (de)
DE (1) DE60232303D1 (de)
DK (1) DK1350109T3 (de)
ES (1) ES2324767T3 (de)
PT (1) PT1350109E (de)
WO (1) WO2002056015A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002210403A1 (en) * 2000-10-20 2002-04-29 Como Biotech Aps Pregnancy-associated plasma protein-a2 (papp-a2)
US6500630B2 (en) * 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
DE60200248T2 (de) 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
EP1962096B1 (de) * 2002-11-16 2012-07-18 Siemens Healthcare Diagnostics Products GmbH SCD40L, PAPP-A und plazentaler-Wachstumsfaktor (PIGF) als biochemische Markerkombination bei kardiovaskulären Erkrankungen
EP1530047A1 (de) * 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximale Markermoleküle der Arterienthrombose und der Entzündung zur Risikostratifizierung einer koronaren Herzkrankheit
DK1882946T3 (da) * 2003-12-23 2010-05-31 Hoffmann La Roche Fremgangsmåde til at bedømme rheumatold arthritis ved at måle anti-CCP og interleukin 6
ES2314624T3 (es) * 2004-01-28 2009-03-16 Turun Yliopisto Metodo mejorado para el diagnostico del sindrome coronario agudo.
JP2007523324A (ja) * 2004-02-05 2007-08-16 メドトロニック・インコーポレーテッド 命にかかわる不整脈のリスク状態にある患者を識別する方法及び装置
US7608458B2 (en) * 2004-02-05 2009-10-27 Medtronic, Inc. Identifying patients at risk for life threatening arrhythmias
US20050287574A1 (en) * 2004-06-23 2005-12-29 Medtronic, Inc. Genetic diagnostic method for SCD risk stratification
US8335652B2 (en) * 2004-06-23 2012-12-18 Yougene Corp. Self-improving identification method
US8027791B2 (en) * 2004-06-23 2011-09-27 Medtronic, Inc. Self-improving classification system
JP2008545139A (ja) * 2005-06-29 2008-12-11 ルールズ−ベースド メディスン，インコーポレーテッド 急性冠症候群の診断方法及び診断キット
CA2629647C (en) * 2005-11-17 2013-05-21 Biogen Idec Ma Inc. Platelet aggregation assays
US20100310462A1 (en) * 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US20100310461A1 (en) * 2007-04-18 2010-12-09 Biochromix Pharma Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
ES2355299T3 (es) * 2007-07-20 2011-03-24 Université De Liége Método combinado para la medición secuencial de (1) la fracción enzimáticamente activa y (2) la cantidad total de una enzima.
US20110143956A1 (en) * 2007-11-14 2011-06-16 Medtronic, Inc. Diagnostic Kits and Methods for SCD or SCA Therapy Selection
EP2222877A4 (de) * 2007-11-14 2011-10-12 Medtronic Inc Genetische marker für die scd- oder sca-therapieauswahl
US8130095B2 (en) 2008-08-27 2012-03-06 The Invention Science Fund I, Llc Health-related signaling via wearable items
US20100056873A1 (en) * 2008-08-27 2010-03-04 Allen Paul G Health-related signaling via wearable items
US8125331B2 (en) 2008-08-27 2012-02-28 The Invention Science Fund I, Llc Health-related signaling via wearable items
US8284046B2 (en) 2008-08-27 2012-10-09 The Invention Science Fund I, Llc Health-related signaling via wearable items
US8094009B2 (en) 2008-08-27 2012-01-10 The Invention Science Fund I, Llc Health-related signaling via wearable items
US20100081928A1 (en) * 2008-09-29 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Histological Facilitation systems and methods
US20100317006A1 (en) * 2009-05-12 2010-12-16 Medtronic, Inc. Sca risk stratification by predicting patient response to anti-arrhythmics
FI20095733A0 (fi) 2009-06-29 2009-06-29 Hytest Oy IGFBP-4-fragmenttien määrittäminen diagnostisena menetelmänä
MX339184B (es) * 2009-09-17 2016-05-16 Hoffmann La Roche Panel multimarcador para hipertrofia ventricular izquierda.
FI20115367A0 (fi) 2011-04-15 2011-04-15 Hytest Oy Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja
WO2013025904A1 (en) * 2011-08-16 2013-02-21 The General Hospital Corporation Apparatus, method and computer-accessible medium for determining antigen immunoreactivity in tissue
CN106460062A (zh) 2014-05-05 2017-02-22 美敦力公司 用于scd、crt、crt‑d或sca治疗识别和/或选择的方法和组合物
US11143659B2 (en) 2015-01-27 2021-10-12 Arterez, Inc. Biomarkers of vascular disease
RU2646490C1 (ru) * 2016-09-16 2018-03-05 Гюзелия Хатыбулловна Каюмова Способ прогнозирования летальности у пациентов с инфарктом миокарда
US11519024B2 (en) * 2017-08-04 2022-12-06 Billiontoone, Inc. Homologous genomic regions for characterization associated with biological targets
CA3071855C (en) 2017-08-04 2021-09-14 Billiontoone, Inc. Target-associated molecules for characterization associated with biological targets
KR102109850B1 (ko) * 2017-08-21 2020-05-13 한양대학교 산학협력단 염증의 유무 예측을 위한 바이오마커

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US525641A (en) * 1894-09-04 Weather-strip
US5039521A (en) * 1989-01-11 1991-08-13 Hyal Pharmaceutical Corporation Immune cell proliferation inhibitors
US5324502A (en) * 1992-04-02 1994-06-28 Purdue Research Foundation Radiopharmaceuticals for imaging the heart
EP0664713B1 (de) * 1992-10-14 2000-01-19 Nycomed Imaging As Therapeutische und diagnostische bilderzeugungzusammensetzung und verfahren zur herstellung
WO1994021686A1 (en) * 1993-03-19 1994-09-29 Northern Sydney Area Health Service Papp-a, its immunodetection and uses
DE69638134D1 (de) * 1995-06-07 2010-04-08 Immunomedics Inc Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort
US6331286B1 (en) * 1998-12-21 2001-12-18 Photogen, Inc. Methods for high energy phototherapeutics
CA2272090A1 (en) 1996-12-09 1998-06-18 Matthew J. Fisher Integrin antagonists
PT1003501E (pt) 1997-04-02 2005-07-29 Brigham & Womens Hospital Utilizacao de um agente para reduzir o risco de doencas cardiovasculares
DE19757250A1 (de) 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
US7115382B1 (en) * 1999-03-15 2006-10-03 Mayo Foundation For Medical Education And Research Method for detecting IGFBP-4 protease without detecting IGFBP-4 protease/proMBP Complex
EP1169058B1 (de) 1999-03-15 2007-05-09 Mayo Foundation For Medical Education And Research Insulinartiger-wachstumsfaktorbindungsprotein-4-protease
US6500630B2 (en) * 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
JP4251617B2 (ja) * 2003-03-10 2009-04-08 キヤノン株式会社 電子機器
US20060063162A1 (en) * 2004-09-23 2006-03-23 Deng David X Biological marker for inflammation

Also Published As

Publication number Publication date
US20100285510A1 (en) 2010-11-11
EP1350109A4 (de) 2004-08-18
EP2081026A1 (de) 2009-07-22
EP1350109B1 (de) 2009-05-13
US20040197844A1 (en) 2004-10-07
US20060110773A1 (en) 2006-05-25
ES2324767T3 (es) 2009-08-14
US20050136498A1 (en) 2005-06-23
PT1350109E (pt) 2009-06-30
CA2434512A1 (en) 2002-07-18
US8323913B2 (en) 2012-12-04
US20090197342A1 (en) 2009-08-06
US20030003521A1 (en) 2003-01-02
US20020132278A1 (en) 2002-09-19
US7723049B2 (en) 2010-05-25
US20070065879A1 (en) 2007-03-22
AU2002241845B2 (en) 2006-11-09
JP2009198510A (ja) 2009-09-03
JP2004531696A (ja) 2004-10-14
JP5226749B2 (ja) 2013-07-03
US20110212024A1 (en) 2011-09-01
DK1350109T3 (da) 2009-08-31
WO2002056015A1 (en) 2002-07-18
CA2434512C (en) 2010-05-11
JP4338972B2 (ja) 2009-10-07
US6500630B2 (en) 2002-12-31
EP1350109A1 (de) 2003-10-08
JP4610660B2 (ja) 2011-01-12
US7939280B2 (en) 2011-05-10
JP2010281833A (ja) 2010-12-16
US6699675B2 (en) 2004-03-02
DE60232303D1 (de) 2009-06-25

Similar Documents

Publication Publication Date Title
ATE431551T1 (de) Marker für entzündungszustände
NO2020005I1 (no) ustekinumab. Forlenget SPC
ATE372131T1 (de) Zubereitung für restenoseprophylaxe
ATE304753T1 (de) Kodeleistungsmessung für dynamische kanalzuwendung
DE60233731D1 (de) Werkstück-positioniervorrichtung
DE60231401D1 (de) Für verstaubare sauerstoffmasken für flugzeugbesatzungen
DK1560584T3 (da) Fab I inhibitorer
CY2012007I2 (el) Πεπτιδομιμητικοι αναστολεις πρωτεασης
DE60116684D1 (de) Linearkompressor
DE60231863D1 (de) Linearkompressor
DE50113812D1 (de) Explosivstoffgetriebene RF-Strahlenquelle
DE60231114D1 (de) Linearkompressor
DE60129947D1 (de) Zusammensetzung für die lasermarkierung
DE50113261D1 (de) Linearwälzlager
DE60142643D1 (de) Aufspuleinrichtung für saiteninstrumente
NO20025786D0 (no) Protaseinhibitorer
DE60225000D1 (de) Linearer kompressor
DE60229669D1 (de) X-2 inhibitoren
NO20025005D0 (no) Proteaseinhibitorer
DE60303231D1 (de) Linearlagerung
DE60209970D1 (de) Metallsubstrat
DE60217480D1 (de) 17-METHYLEN-ANDROSTAN-3a-OL-ANALOGA ALS CRH- INHIBITOREN
ATE535775T1 (de) Präzisionsdendrometer
DK1130214T3 (da) Korrosionsinhibitorer
DE50303710D1 (de) Linearwälzlager

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1350109

Country of ref document: EP